Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Risk Factors of Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia Patients: A Single-Center Experience

Soyoon MIN, MD, Hyery Kim, MD, Juhee Shin, Jin Kyung Suh, MD, Sung Han Kang, MD, Kyung-Nam Koh, MD, Ho Joon Im, MD, Jong Jin Seo, MD

Blood (2019) 134 (Supplement_1): 5077.

https://doi.org/10.1182/blood-2019-128236

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Optimal Use of Thai Sinlek Rice (IR) Provides the Nutraceutical Effect on Erythropoiesis in Rats

Pimpisid Koonyosying, PhD, Ben Flemming, BSc, Supachai Ekwattanakit, PhDMD, Vip Viprakasit, MD DPhil, Suthat Fucharoen, MD, Somdet Srichairatanakool, PhD

Blood (2019) 134 (Supplement_1): 4808.

https://doi.org/10.1182/blood-2019-129679

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Pancreatic Iron Deposition Following the Role of Iron Loading Among Transfusion Dependent Sickle Cell Disease Egyptian Children and Young Adults

Mohsen Saleh Elalfy, MD, Khalid Allam, MD, Ahmed Ibrahim, MD, Basant Mosaad, MD, Fatma Soliman Elsayed Ebeid, MD

Blood (2019) 134 (Supplement_1): 4828.

https://doi.org/10.1182/blood-2019-123683

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD

Blood (2018) 132 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2018-99-111648

Published: 2018

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Jonathan Webster, MD, Marlise R. Luskin, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, Daniel J. DeAngelo, MD, Mark J. Levis, MD, Amanda Blackford, Elad Sharon, MD MPH, Howard Streicher, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2018) 132 (Supplement 1): 557.

https://doi.org/10.1182/blood-2018-99-111845

Published: 2018

Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2018-99-116338

Published: 2018

Journal Articles

A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation

Nitin Jain, MD, Alessandra Ferrajoli, MD, Sreyashi Basu, PhD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Naveen Pemmaraju, MD, Wanda Lopez, RN, Beenu Thakral, MD, Joseph David Khoury, MD, Carlos E. Bueso-Ramos, MD PhD, Jorge Blando, DVM, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, James P Allison, PhD, Michael J Keating, MBBS, Padmanee Sharma, MD PhD, William G. Wierda, MD PhD

Blood (2018) 132 (Supplement 1): 296.

https://doi.org/10.1182/blood-2018-99-120355

Published: 2018

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2018-99-119944

Published: 2018

Journal Articles

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Francois Xavier Gros, MD, Pierre-Yves Dumas, MD, Edouard Forcade, MD, Claire Calmettes, MD, Margot Robles, MD, Vincent Servant, PharmD, Nicolas Lechevalier, PharmD, Audrey Bidet, PharmD, Noel Milpied, Arnaud Pigneux, MD PhD, Thibaut Leguay, MD

Blood (2017) 130 (Supplement 1): 1296.

https://doi.org/10.1182/blood.V130.Suppl_1.1296.1296

Published: 2017

Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD

Blood (2017) 130 (Supplement 1): 2622.

https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622

Published: 2017

Journal Articles

Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study

Benjamin Ole Wolthers, MD, Thomas Leth Frandsen, MD PhD, Andishe Attarbaschi, MD, Shlomit Barzilai, MD, Antonella Colombini, Gabriele Escherich, MD, Marie Grosjean, Ramneek Gupta, PhD, Der-Cherng Liang, MD, Anja Moricke, MD, Chirag J Patel, PhD, Kirsten K Rasmussen, Sujith Samarasinghe, Inge M. Van Der Sluis, MD PhD, Martin Stanulla, MD PhD, Morten Tulstrup, MD, Ester Zapotocka, MD, Kjeld Schmiegelow, MD DMSc

Blood (2017) 130 (Supplement 1): 885.

https://doi.org/10.1182/blood.V130.Suppl_1.885.885

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

NARROW

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Risk Factors of Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia Patients: A Single-Center Experience

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Optimal Use of Thai Sinlek Rice (IR) Provides the Nutraceutical Effect on Erythropoiesis in Rats

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Pancreatic Iron Deposition Following the Role of Iron Loading Among Transfusion Dependent Sickle Cell Disease Egyptian Children and Young Adults

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only